Keyphrases
Israel
100%
Extended-spectrum-lactamase
52%
Klebsiella Pneumoniae (K. pneumoniae)
51%
Enterobacteriaceae
49%
Carbapenem-resistant Acinetobacter Baumannii
48%
Bloodstream Infection
47%
Risk Factors
41%
Escherichia Coli
38%
Pseudomonas Aeruginosa (P. aeruginosa)
36%
Klebsiella Pneumoniae Carbapenemase
33%
Methicillin-resistant Staphylococcus Aureus
31%
Israeli
31%
Carbapenem-resistant Enterobacteriaceae
29%
Plasmid
29%
Carbapenemase-producing Enterobacterales
28%
Carbapenems
27%
Colistin
27%
Imipenem
26%
Confidence Interval
26%
Antibiotics
24%
Multidrug-resistant Pseudomonas Aeruginosa (MDRPA)
24%
Carbapenem Resistance
24%
Antimicrobial Resistance
24%
Bacteremia
23%
KPC-2
22%
Odds Ratio
21%
Hospitalized Patients
21%
Europe
20%
Infection Control
19%
Carbapenemase-producing
19%
Carbapenemase
18%
Ertapenem
18%
Vancomycin-resistant Enterococci
17%
Antibiotic Resistance
17%
β-lactamase
17%
Acinetobacter Baumannii (A. baumannii)
16%
Staphylococcus Aureus
16%
Ceftazidime
16%
Tel Aviv
15%
KPC-producing Klebsiella Pneumoniae
15%
Acute Hospital
14%
Clostridioides Difficile
14%
Epidemiology
14%
Cephalosporins
14%
Meropenem
14%
Vancomycin
14%
Enterobacterales
14%
Ciprofloxacin
14%
Lactams
13%
Medical Center
13%
Pharmacology, Toxicology and Pharmaceutical Science
Infection
74%
Carbapenem
72%
Bloodstream Infection
56%
Pseudomonas aeruginosa
41%
Penicillinase
39%
Klebsiella pneumoniae
34%
Escherichia coli
30%
Extended Spectrum Beta Lactamase
28%
Carbapenemase
27%
Enterobacteriaceae
27%
Imipenem
26%
Antibiotics
24%
Antimicrobial Resistance
24%
Infectious Agent
23%
Acinetobacter Baumannii
22%
Colistimethate
22%
Gram Negative Bacterium
22%
Carbapenem Resistant Enterobacteriaceae
19%
Staphylococcus Aureus
17%
Antiinfective Agent
16%
Prevalence
15%
Cohort Study
14%
Carbapenem Derivative
14%
Meropenem
13%
Carbapenemase Producing Enterobacteriaceae
12%
Ceftazidime
12%
Quinolone Derivative
11%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
11%
Diseases
11%
Methicillin-Resistant Staphylococcus Aureus
11%
Ertapenem
11%
Lactam
10%
Clostridium Difficile Infection
10%
Combination Therapy
10%
Cephalosporin Derivative
10%
Meticillin
9%
Case-Control Study
9%
Vancomycin
9%
Avibactam Plus Ceftazidime
8%
Antimicrobial Therapy
8%
Piperacillin Plus Tazobactam
8%
Ciprofloxacin
8%
Third Generation Cephalosporin
7%
Randomized Controlled Trial
7%
Surgical Infection
7%
Acinetobacter Infection
7%
Monotherapy
6%
Wound Infection
6%
Hospital Infection
6%
Abdominal Infection
6%
Medicine and Dentistry
Infection
52%
Carbapenem
49%
Bloodstream Infection
40%
Penicillinase
39%
Enterobacteriaceae
34%
Acinetobacter Baumannii
28%
Klebsiella pneumoniae
27%
Extended Spectrum Beta Lactamase
26%
Carbapenemase
24%
Infection Control
22%
Carbapenem-Resistant Enterobacteriaceae
22%
Antibiotic Resistance
22%
Beta-Lactamase
21%
Pseudomonas aeruginosa
21%
Antibiotics
20%
Extended Spectrum Beta Lactamase Producing Enterobacteriaceae
19%
Escherichia coli
18%
Antiinfective Agent
17%
Pathogen
16%
Gram-Negative Bacteria
16%
Cohort Effect
16%
Odds Ratio
14%
Carbapenemase Producing Enterobacteriaceae
14%
Ertapenem
14%
Prevalence
13%
Staphylococcus Aureus
13%
Colistimethate
12%
Imipenem
12%
Cohort Analysis
12%
Carbapenem Derivative
10%
Clostridium Difficile Infection
10%
Intensive Care Unit
10%
Systematic Review
10%
Meropenem
9%
Vancomycin Resistant Enterococcus
9%
Methicillin Resistant Staphylococcus Aureus
9%
Infection Prevention
8%
Antibiogram
8%
Peptoclostridium difficile
8%
Rehabilitation Center
8%
Ceftazidime
8%
Subacute Care
8%
Avibactam Plus Ceftazidime
8%
Piperacillin/Tazobactam
8%
Public Health
7%
Enterobacter
7%
Tertiary Care
7%
Randomized Controlled Trial
6%
Antibiotic Therapy
6%
Abdominal Infection
6%